Geode Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Geode Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$335K	Buy	336,073 +7,079	+2%	+$8.42K	﹤0.01%	3726
2025 Q4	$448K	Buy	328,994 +575	+0.2%	+$839	﹤0.01%	3622
2025 Q3	$526K	Sell	328,419 -1,270	-0.4%	-$2.07K	﹤0.01%	3596
2025 Q2	$462K	Sell	329,689 -382,112	-54%	-$572K	﹤0.01%	3579
2025 Q1	$1.15M	Buy	711,801 +23,948	+3%	+$30.4K	﹤0.01%	3257
2024 Q4	$867K	Buy	687,853 +1,700	+0.2%	+$2.64K	﹤0.01%	3420
2024 Q3	$1.29M	Buy	686,153 +19,843	+3%	+$78.4K	﹤0.01%	3264
2024 Q2	$4.93M	Buy	666,310 +70,590	+12%	+$581K	﹤0.01%	2731
2024 Q1	$4.67M	Buy	595,720 +26,171	+5%	+$168K	﹤0.01%	2741
2023 Q4	$2.89M	Buy	569,549 +27,110	+5%	+$140K	﹤0.01%	2970
2023 Q3	$3.21M	Buy	542,439 +21,058	+4%	+$140K	﹤0.01%	2866
2023 Q2	$3.87M	Buy	521,381 +288,949	+124%	+$2.46M	﹤0.01%	2829
2023 Q1	$2.2M	Buy	232,432 +746	+0.3%	+$7.87K	﹤0.01%	2986
2022 Q4	$2.47M	Buy	231,686 +17,520	+8%	+$178K	﹤0.01%	2961
2022 Q3	$1.58M	Buy	214,166 +41,949	+24%	+$261K	﹤0.01%	3172
2022 Q2	$828K	Buy	172,217 +5,045	+3%	+$28.6K	﹤0.01%	3509
2022 Q1	$854K	Hold	167,172	–	–	﹤0.01%	3686
2021 Q4	$1M	Hold	167,172	–	–	﹤0.01%	3719
2021 Q3	$1.48M	Buy	167,172 +14,494	+9%	+$101K	﹤0.01%	3494
2021 Q2	$1.21M	Buy	152,678 +52,872	+53%	+$415K	﹤0.01%	3501
2021 Q1	$760K	Hold	99,806	–	–	﹤0.01%	3667
2020 Q4	$778K	Hold	99,806	–	–	﹤0.01%	3445
2020 Q3	$967K	Buy	99,806 +12,693	+15%	+$140K	﹤0.01%	3225
2020 Q2	$918K	Buy	87,113 +67,000	+333%	+$507K	﹤0.01%	3165
2020 Q1	$117K	Buy	20,113 +248	+1%	+$1.76K	﹤0.01%	3717
2019 Q4	$129K	Buy	19,865 +258	+1%	+$1.78K	﹤0.01%	3928
2019 Q3	$135K	Hold	19,607	–	–	﹤0.01%	3883
2019 Q2	$144K	Buy	19,607 +5,193	+36%	+$52.2K	﹤0.01%	3865
2019 Q1	$207K	Hold	14,414	–	–	﹤0.01%	3730
2018 Q4	$167K	Hold	14,414	–	–	﹤0.01%	3723
2018 Q3	$320K	Buy	14,414 +4,002	+38%	+$81.5K	﹤0.01%	3602
2018 Q2	$199K	Buy	10,412 +4,037	+63%	+$51.2K	﹤0.01%	3720
2018 Q1	$69K	Hold	6,375	–	–	﹤0.01%	3907
2017 Q4	$126K	Hold	6,375	–	–	﹤0.01%	3770
2017 Q3	$109K	Hold	6,375	–	–	﹤0.01%	3810
2017 Q2	$233K	Buy	6,375 +1,332	+26%	+$55.7K	﹤0.01%	3627
2017 Q1	$228K	Hold	5,043	–	–	﹤0.01%	3610
2016 Q4	$132K	Hold	5,043	–	–	﹤0.01%	3725
2016 Q3	$204K	Hold	5,043	–	–	﹤0.01%	3592
2016 Q2	$267K	Hold	5,043	–	–	﹤0.01%	3471
2016 Q1	$301	Hold	5,043	–	–	﹤0.01%	3476
2015 Q4	$488K	Hold	5,043	–	–	﹤0.01%	3287
2015 Q3	$267K	Hold	5,043	–	–	﹤0.01%	3541
2015 Q2	$400K	Sell	5,043 -7	-0.1%	-$597	﹤0.01%	3298
2015 Q1	$374K	Buy	5,050 +139	+3%	+$16.5K	﹤0.01%	3316
2014 Q4	$867K	Hold	4,911	–	–	﹤0.01%	2930
2014 Q3	$987K	Buy	4,911 +1,202	+32%	+$238K	﹤0.01%	2785
2014 Q2	$803K	Buy	+3,709	New	+$1.24M	﹤0.01%	2924

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management's ATNM Position: Q1 2026 in Review

Geode Capital Management increased its Actinium Pharmaceuticals (ATNM) stake by 2.2% in Q1 2026, buying an estimated $8.42K and bringing the position to 336,073 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #3726.

Geode Capital Management first reported a position in ATNM in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.93M in Q2 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Geode Capital Management held 336,073 shares of Actinium Pharmaceuticals worth $335K as of Q1 2026.
Geode Capital Management bought 7,079 Actinium Pharmaceuticals shares in Q1 2026, an estimated $8.42K.
Actinium Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3726 holding.
Geode Capital Management first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
Geode Capital Management's Actinium Pharmaceuticals position peaked at $4.93M in Q2 2024.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.